Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function
Recruiting
Observational Study
Renal Osteodystrophy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 40 (estimated)
- Sponsor
- Ditte Hansen · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of the study is to 1. To describe the bone morphology in patients with reduced renal function and high or low parathyroid hormone (PTH) respectively. 2. To investigate if the non-invasive method 18-Fluoride Positron Emission Tomography (18F-PET) can describe the bone turnover and reflect the bone histomorphologic changes 3. To investigate if non-oxidized PTH reflects bone turnover
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Patients with reduced renal function:
Inclusion Criteria:
-≥ 18 years
* estimated Glomerular Filtration Rate (eGFR) ≤ 20 ml/min/1,73m2
* PTH \< 150 pg/ml or PTH \> 300 pg/ml
Exclusion Criteria:
* ongoing malignancy
* Allergy towards tetracyclin
* Pregnancy
Control Group:
Inclusion Criteria:
…
Contacts